Novartis has reported positive results from a pooled analysis of four Phase III clinical trials evaluating Cosentyx (secukinumab) in patients with moderate-to-severe plaque psoriasis (PsO).
PsO is characterised by painful red, raised, dry patches of skin and usually attacks extensor areas of the forearms and shins as well as the scalp, palms of the hand, soles of the feet and fingernails.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Cosentyx is a fully human IL-17A antagonist approved to treat moderate to severe PsO, psoriatic arthritis (PsA), and ankylosing spondylitis (AS).
The latest analysis showed that patients treated with Cosentyx 300mg achieved improvements in mobility, self-care, and usual activities components as measured by the EQ-5D-3L questionnaire at week four.
Wake Forest School of Medicine representative Steven Feldman, who receives research support from Novartis, said: “Moderate-to-severe plaque psoriasis can impact every aspect of a person’s life.
“These findings suggest that helping patients feel better through improved quality of life and ability to function should be a goal as important as skin clearance in psoriasis management.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe pooled analysis is based on data gained from the ERASURE, FIXTURE, FEATURE, and JUNCTURE trials, which enrolled patients with moderate-to-severe psoriasis.
The trials saw 309 patients treated with Cosentyx 300mg and 282 patients receive placebo.
Patients who reported problems with mobility, self-care, or usual activities at baseline were also included in the trial.
The trials compared the percentages of patients reporting problems in the EQ-5D-3L mobility, self-care, or usual activities at weeks four, eight and 12.
